We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PacBio (PACB) New Revio Workflows to Boost Agricultural Output
Read MoreHide Full Article
Pacific Biosciences of California (PACB - Free Report) or PacBio collaborated with global agriculture firm, Corteva Agriscience (CTVA - Free Report) , to develop innovative workflows that enable high-throughput sequencing of plant and microbial genomes. The workflows streamline DNA extraction and library preparation, allowing Corteva to sequence thousands of samples annually for seed and crop protection research and production. This partnership, which started at the Advances in Genome Biology and Technology Agricultural meeting last year, provides novel end-to-end workflows that are cost-effective and designed to support ultra-high throughput long-read sequencing.
The initial phase of the collaboration involved the development of scaled DNA extraction, shearing and library preparation workflows to characterize Corteva's extensive collection of crop and microbial samples. These workflows were designed to facilitate transformative crop genetic and diversity studies. The engineering involved the use of ultra-high throughput long-read sequencing on PacBio's revolutionary Revio system and Nanobind products.
Significance of New Workflows
PacBio’s collaboration with Corteva Agriscience will support its efforts to offer healthier and more sustainable production of plants to farmers. With the increasing world population, Corteva believes that new methods in the field of crop science are required to sustainably meet the increasing need for food production. The workflows, along with the new long-read sequencing Revio system, will drive the implementation of seed product development tools like CRISPR-Cas gene editing and cutting-edge crop protection solutions.
With the successful results of this collaboration, both companies plan to continue expanding sequencing capabilities and sample preparation workflows into new application areas, fostering a long-term partnership dedicated to revolutionizing agriculture.
Industry Prospects
Per a report by Data Bridge, the global genome sequencing market is projected to reach $55.7 billion in 2030 from $16.7 billion in 2022, at a CAGR of 16.2%. Factors like increasing cancer occurrence and the growing applications of next-generation sequencing in cancer research are expected to drive the market.
Given the market potential, the latest launch is expected to significantly strengthen PacBio’s global business.
Earlier this month, PacBio introduced a new informatics tool, Paraphase, for variant calling, copy number analysis and phasing. It does so by identifying the full sequence of each of the haplotypes for all genes and pseudogenes of the same gene family. Paraphase has been used on various medically relevant genes, including those related to spinal muscular atrophy, congenital adrenal hyperplasia, Ehlers-Danlos syndrome, and hereditary hearing loss and deafness. With the help of this tool, researchers can better understand the underlying genetics of these complex genomic regions. They can also identify the silent carriers of disease-causing mutations.
In March, PacBio started commercial shipment of Revio long-read sequencing system. It is designed to deliver higher throughput on a lower cost, offering exceptional accuracy and direct methylation detection.
The company expects to ship at least 25 Revio systems and plans to scale up going forward. It had received orders of 76 systems during the fourth quarter of 2022. Last month, the company announced robust increase in its Consumables revenues during the same quarter. However, service and other revenues, as well as product sales declined year over year.
Zacks Rank & Stocks to Consider
PacBiocurrently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Becton, Dickinson and Company (BDX - Free Report) and Henry Schein (HSIC - Free Report) .
Becton, Dickinson and Company, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth of 7.8%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.47%.
BDX’s shares have declined 9.9% against the industry’s 0.7% growth in the past six months.
Henry Schein, carrying a Zacks Rank #2 at present, has an estimated long-term growth of 8.1%. Its earnings surpassed estimates in three of the trailing four quarters and met the same once, the average surprise being 2.97%.
HSIC’s shares have gained 7.8% compared with the industry’s 0.8% growth in the past six months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
PacBio (PACB) New Revio Workflows to Boost Agricultural Output
Pacific Biosciences of California (PACB - Free Report) or PacBio collaborated with global agriculture firm, Corteva Agriscience (CTVA - Free Report) , to develop innovative workflows that enable high-throughput sequencing of plant and microbial genomes. The workflows streamline DNA extraction and library preparation, allowing Corteva to sequence thousands of samples annually for seed and crop protection research and production. This partnership, which started at the Advances in Genome Biology and Technology Agricultural meeting last year, provides novel end-to-end workflows that are cost-effective and designed to support ultra-high throughput long-read sequencing.
The initial phase of the collaboration involved the development of scaled DNA extraction, shearing and library preparation workflows to characterize Corteva's extensive collection of crop and microbial samples. These workflows were designed to facilitate transformative crop genetic and diversity studies. The engineering involved the use of ultra-high throughput long-read sequencing on PacBio's revolutionary Revio system and Nanobind products.
Significance of New Workflows
PacBio’s collaboration with Corteva Agriscience will support its efforts to offer healthier and more sustainable production of plants to farmers. With the increasing world population, Corteva believes that new methods in the field of crop science are required to sustainably meet the increasing need for food production. The workflows, along with the new long-read sequencing Revio system, will drive the implementation of seed product development tools like CRISPR-Cas gene editing and cutting-edge crop protection solutions.
With the successful results of this collaboration, both companies plan to continue expanding sequencing capabilities and sample preparation workflows into new application areas, fostering a long-term partnership dedicated to revolutionizing agriculture.
Industry Prospects
Per a report by Data Bridge, the global genome sequencing market is projected to reach $55.7 billion in 2030 from $16.7 billion in 2022, at a CAGR of 16.2%. Factors like increasing cancer occurrence and the growing applications of next-generation sequencing in cancer research are expected to drive the market.
Given the market potential, the latest launch is expected to significantly strengthen PacBio’s global business.
Pacific Biosciences of California, Inc. Price
Pacific Biosciences of California, Inc. price | Pacific Biosciences of California, Inc. Quote
Recent Developments
Earlier this month, PacBio introduced a new informatics tool, Paraphase, for variant calling, copy number analysis and phasing. It does so by identifying the full sequence of each of the haplotypes for all genes and pseudogenes of the same gene family. Paraphase has been used on various medically relevant genes, including those related to spinal muscular atrophy, congenital adrenal hyperplasia, Ehlers-Danlos syndrome, and hereditary hearing loss and deafness. With the help of this tool, researchers can better understand the underlying genetics of these complex genomic regions. They can also identify the silent carriers of disease-causing mutations.
In March, PacBio started commercial shipment of Revio long-read sequencing system. It is designed to deliver higher throughput on a lower cost, offering exceptional accuracy and direct methylation detection.
The company expects to ship at least 25 Revio systems and plans to scale up going forward. It had received orders of 76 systems during the fourth quarter of 2022. Last month, the company announced robust increase in its Consumables revenues during the same quarter. However, service and other revenues, as well as product sales declined year over year.
Zacks Rank & Stocks to Consider
PacBiocurrently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Becton, Dickinson and Company (BDX - Free Report) and Henry Schein (HSIC - Free Report) .
Becton, Dickinson and Company, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth of 7.8%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.47%.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
BDX’s shares have declined 9.9% against the industry’s 0.7% growth in the past six months.
Henry Schein, carrying a Zacks Rank #2 at present, has an estimated long-term growth of 8.1%. Its earnings surpassed estimates in three of the trailing four quarters and met the same once, the average surprise being 2.97%.
HSIC’s shares have gained 7.8% compared with the industry’s 0.8% growth in the past six months.